RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis

Keyphrases

• Monoclonal Antibody 100%
• Interleukin-13 (IL-13) 100%
• Eosinophilic Esophagitis 100%
• Endoscopic Activity 100%
• Histologic Activity 100%
• Placebo 50%
• Eosinophil Count 50%
• Phase II Trial 33%
• Histopathological Features 33%
• Dysphagia Symptoms 33%
• Endoscopic Features 33%
• High-power Field 33%
• Symptom Diary 33%
• Patient-Reported Outcomes Measurement Information System (PROMIS) 16%
• Headache 16%
• Inflammation 16%
• Inflammatory Response 16%
• Serum Levels 16%
• Disease Severity 16%
• Adverse Events 16%
• IL-13Rα2 16%
• Upper Respiratory Tract Infection 16%
• Change in Mean 16%
• Receptor Subunits 16%
• Double-blind Trial 16%
• Placebo Groups 16%
• Global Assessment 16%
• Recombinant Antibody 16%
• Patient-completed 16%
• Once-weekly 16%
• Histological Grade 16%
• Severity Score 16%
• Esophagogastroduodenoscopy 16%
• Steroid-refractory 16%
• IL-13Rα1 16%

Medicine and Dentistry

• Eosinophilic Esophagitis 100%
• Interleukin 13 100%
• Monoclonal Antibody 100%
• Placebo 66%
• Eosinophil 50%
• Plummer-Vinson Syndrome 33%
• Adverse Event 16%
• Receptor Subunit 16%
• Serositis 16%
• Upper Respiratory Tract Infection 16%
• Headache 16%
• Patient-Reported Outcome 16%
• Disease Severity 16%
• Biopsy Technique 16%
• Esophagogastroduodenoscopy 16%
• Clinician 16%